Atrium Health Levine Cancer | Strategic Alliance Partners

January 08, 2024

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

December 19, 2023

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

December 10, 2023

Venetoclax-based therapy generated durable responses both overall and in the second or third line following covalent BTK inhibitor discontinuation in real-world patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

November 01, 2023

Steven I. Park, MD, discusses the unique design of the SYMPHONY-1 trial, the importance of enrolling patients to the phase 3 portion of the study, and why tazemetostat in combination with lenalidomide and rituximab could represent an effective and tolerable therapeutic option for frail or older patients with relapsed/refractory follicular lymphoma.

October 26, 2023

Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, mismatch repair–deficient disease.

October 10, 2023

Professional and personal satisfaction are both possible with a hybrid option that optimizes work-life balance.

September 20, 2023

Steven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.

August 19, 2023

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.

June 28, 2023

Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.

June 19, 2023

Ryan Jacobs, MD, hematologist and medical oncologist, Levine Cancer Institute, Atrium Health, discusses early responses with the novel CD19 and CD3 T-cell engager TNB-486 in relapsed/refractory follicular lymphoma according to a phase 1 study.

May 18, 2023

Antoinette R. Tan, MD, MHSc, discussed the promise of oral SERDs as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.

May 17, 2023

Alaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.

May 16, 2023

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

May 10, 2023

Neelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

April 28, 2023

Erin K. Crane, MD, MPH, discusses findings from 3 trials demonstrating the benefits of PARP inhibitor maintenance in patients with ovarian cancer.

April 15, 2023

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.

March 27, 2023

Alaa Muslimani, MD, discusses the unmet needs for patients with HER2-positve metastatic colorectal cancer and highlights the implications of the phase 2 MOUNTAINEER trial in this patient population.

March 24, 2023

Joshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.

March 23, 2023

Jimmy Hwang, MD, discusses findings supporting the use of immunotherapy in hepatocellular carcinoma and biliary tract cancer, the potential benefits of antibody-drug conjugates in metastatic colorectal cancer, and unmet needs in esophageal squamous cell carcinoma and rectal cancer.

March 17, 2023

Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.